Paul joined NEA in 2008. He focuses on later-stage life sciences investments. Prior to joining NEA, Paul worked at MPM Capital as a General Partner with the MPM BioEquities Fund, where he specialized in public, PIPE and mezzanine-stage life sciences investing. Previously, he was a portfolio manager at Franklin Templeton Investments. Paul received a BS in Biochemistry and Cell Biology from the University of California at San Diego, and holds the Chartered Financial Analyst (CFA) designation. He is a Director of Allakos (NASDAQ: ALLK), TRACON Pharmaceuticals (NASDAQ: TCON), and Trillium Therapeutics (NASDASQ: TRIL); he was previously a Director of TESARO (NASDAQ: TSRO) and manages a number of NEA’s public healthcare investments.
- October 3, 2018